Search Result

Results for "

PCSK9 inhibitor

" in MedChemExpress (MCE) Product Catalog:

By Targets:	PCSK9 (58) Amyloid-β (1) ANGPTL (1) Apoptosis (1) Autophagy (1) Caspase (2) CX3CR1 (2) Fatty Acid Synthase (FASN) (1) HMG Family (2) HSV (1) Interleukin Related (3) Keap1-Nrf2 (2) LDLR (2) NF-κB (3) NOD-like Receptor (NLR) (4) PPAR (2) Pyroptosis (2) Ser/Thr Protease (3) Small Interfering RNA (siRNA) (3) Toll-like Receptor (TLR) (1)
By Research Areas:	Cancer (8) Cardiovascular Disease (37) Infection (1) Inflammation/Immunology (2) Metabolic Disease (30) Neurological Disease (1)
Oligonucleotides:	siRNA drugs (6) Antisense Oligonucleotides (7) siRNAs (6)

Inhibitors & Agonists

Peptides

Inhibitory Antibodies

Natural
Products

Oligonucleotides

Targets Recommended: PCSK9

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-157434

PCSK9-IN-23	PCSK9	Cardiovascular Disease
PCSK9-IN-23 (compound 5C) is a potent *PCSK9* inhibitor. PCSK9-IN-23 blocks PCSK9 secretion from HepG2 cells, significantly increases LDL receptor (LDLR) expression .

HY-152221

PCSK9-IN-10	PCSK9	Cardiovascular Disease Metabolic Disease
PCSK9-IN-10 is a potent and orally active *PCSK9* inhibitor with an IC₅₀ value of 6.4 µM. PCSK9-IN-10 increases the expression of LDLR protein and decreases the expression of PCSK9. PCSK9-IN-10 reduces atherosclerosis progression. PCSK9-IN-10 has the potential for the research of hyperlipidemia .

HY-152223

PCSK9-IN-11	PCSK9	Cardiovascular Disease
PCSK9-IN-11 (compound 5r) is a potent and orally active *PCSK9* inhibitor. PCSK9-IN-11 exhibits PCSK9 transcriptional inhibitory activity in HepG2 cells, with an IC₅₀ of 5.7 μM. PCSK9-IN-11 increases LDL receptor (LDLR) protein level. PCSK9-IN-11 can be used for atherosclerosis research .

HY-161940

PCSK9-IN-30	PCSK9	Cardiovascular Disease
PCSK9-IN-30 (Compound 3f) is a *PCSK9* inhibitor. PCSK9-IN-30 interacts with a cryptic binding groove of *PCSK9, inhibiting* the binding of *PCSK9* to the low-density lipoprotein receptor (LDLR) (IC₅₀ = 537 nM), restoring the uptake of low-density lipoprotein (LDL) by liver cells, and ultimately reducing plasma cholesterol levels. PCSK9-IN-30 exhibits good bioavailability in mice and can be used for research in the field of cardiovascular diseases .

HY-160036

PCSK9-IN-22	PCSK9	Metabolic Disease
PCSK9-IN-22 (compound 29) is an orally active inhibitor of *PCSK9. PCSK9-IN-22 inhibits* the interaction of the protein with LDLR in vivo .

HY-155415

PCSK9-IN-20	PCSK9	Cardiovascular Disease
PCSK9-IN-20 (Compound 3i) is a *PCSK9* inhibitor with an IC₅₀ of 3.96 µM. PCSK9-IN-20 decreases PCSK9 and increases LDLR protein expression in vitro .

HY-162562

E28362	PCSK9	Cardiovascular Disease
E28362 is a novel small molecule *PCSK9* inhibitor. E28362 blocks the interaction between *PCSK9* and LDLR, thereby preventing the degradation of LDLR and maintaining cholesterol homeostasia. E28362 is a promising lead compound for the study of hyperlipidemia and atherosclerosis .

HY-N10702

PCSK9-IN-9	PCSK9	Cardiovascular Disease
PCSK9-IN-9 is an isocoumarins of natural origin. PCSK9-IN-9 can inhibit proprotein convertase subtilisin-kexin type 9 (PCSK9), IDOL, and SREBP2 mRNA expression. PCSK9-IN-9 inhibits *PCSK9* with an IC₅₀ value of 11.9 μM .

HY-161434

PCSK9-IN-26	PCSK9	Metabolic Disease
PCSK9-IN-26 (Compound 116) is an *PCSK9* inhibitor (IC₅₀ < 1 nM). PCSK9-IN-26 can be used for metabolic research .

HY-153453

PCSK9-IN-17	PCSK9	Cardiovascular Disease
PCSK9-IN-17 is a *PCSK9* inhibitor. PCSK9-IN-17 can be used for the research of cholesterol metabolism (WO2020150474A1, compound 105) .

HY-161435

PCSK9-IN-27	PCSK9	Metabolic Disease
PCSK9-IN-27 (Compound 108) is a *PCSK9* inhibitor (IC₅₀: 3.4 nM). PCSK9-IN-27 reduces LDLR degradation and increases LDL-C uptake .

HY-155006

PCSK9-IN-19	PCSK9	Metabolic Disease
PCSK9-IN-19 (Compound 1) is a *PCSK9* inhibitor. PCSK9-IN-19 can be used for research of high LDL-cholesterol levels and prevention of coronary artery disease .

HY-153454

PCSK9-IN-18	PCSK9	Metabolic Disease
PCSK9-IN-18 (compound 188) is a potent *PCSK9* inhibitor with a K_D value of <200 nM .

HY-153391

PCSK9-IN-14	PCSK9	Metabolic Disease
PCSK9-IN-14 (compound Ia-8) is a potent *PCSK9* inhibitor .

HY-153452

PCSK9-IN-16	PCSK9	Cardiovascular Disease
PCSK9-IN-16 is a potent *PCSK9* inhibitor. PCSK9-IN-16 is extracted from patent WO2020150474, example 87, has the potential for hypercholesterolemia and other cardiovascular diseases research .

HY-134482

PCSK9-IN-1	PCSK9	Cardiovascular Disease
PCSK9-IN-1 is a novel and highly potent cyclic peptide *PCSK9* inhibitor with a K_i value of 1.46 nM.

HY-148758

PCSK9-IN-13	PCSK9	Cardiovascular Disease Metabolic Disease
PCSK9-IN-13(compound 3f) is a potent *PCSK9* inhibitor, which can antagonize low-density lipoprotein (LDL) receptor binding by binding to PCSK9, with an IC₅₀ of 537 nM .

HY-139998

PCSK9-IN-3	PCSK9	Cardiovascular Disease
PCSK9-IN-3 is a novel, highly potent, and orally bioavailable next-generation tricyclic peptide *PCSK9* inhibitor.

HY-168156

PCSK9-IN-32	PCSK9	Cancer
PCSK9-IN-32 (compund 8) is a *PCSK9*[1:33]-GFP translation inhibitor .

HY-153451

PCSK9-IN-15	PCSK9	Metabolic Disease
PCSK9-IN-15 (compound 5) is a potent inhibitor of proprotein convertase subtilisin/kexin 9 (PCSK9, K_D <200 nM). PCSK9 is involved in cholesterol metabolism and regulates levels of low-density lipoprotein cholesterol (LDL-C) in the blood. PCSK9- in -15 can be used to study cholesterol-lowering and dyslipidemia .

HY-N13083

PCSK9-IN-28	PCSK9	Cardiovascular Disease
PCSK9-IN-28 (Compound C11) is a *PCSK9* inhibitor that can be isolated from Euphorbia esula. By binding to HNF1α, PCSK9-IN-28 inhibits PCSK9 transcription by binding to HNF1α and affecting its nuclear distribution, thereby enhancing LDLR and promoting LDL uptake. PCSK9-IN-28 exhibits significant lipid-lowering activity in the high-fat diet (HFD) mouse model and can be used in the study of hyperlipidemia .

HY-149310

Dim16	Ser/Thr Protease	Metabolic Disease
Dim16 is a dual *PCSK9/HMG-CoAR* inhibitor, with an IC₅₀ value of 19 nM for PCSK9. Dim16 inhibits PCSK9-LDLR binding with an IC₅₀ value of 0.8 nM. Dim16 increases LDL uptake in HepG2 cells .

HY-161942

PCSK9-IN-31	PCSK9	Metabolic Disease
PCSK9-IN-31 (Compound WX002) is an orally active *PCSK9* inhibitor. PCSK9-IN-31 can lower low-density lipoprotein cholesterol (LDL-C) and total cholesterol (TC) in high cholesterol fed model rats .

HY-132897

PCSK9-IN-2	PCSK9	Cardiovascular Disease
PCSK9-IN-2 is a novel small molecule inhibitor of *PCSK9-LDLR* protein–protein interaction (PPI) with an IC₅₀ value of 7.57 μM.

HY-P99626

Frovocimab LY 3015014	PCSK9	Metabolic Disease
Frovocimab (LY 3015014) is a humanized IgG4 monoclonal antibody (mAb) that neutralizes *PCSK9. Frovocimab inhibits* PCSK9 binding to LDL receptor (LDLR) while permitting the normal proteolytic cleavage of the bound intact PCSK9 .

HY-P9928A

Alirocumab (anti-PCSK9) 1 Publications Verification REGN 727(anti-PCSK9); SAR 236553(anti-PCSK9)	PCSK9 NOD-like Receptor (NLR) Keap1-Nrf2 HMG Family NF-κB CX3CR1	Cardiovascular Disease Cancer
Alirocumab (anti-PCSK9) is an anti-PCSK9 human monoclonal antibody. Alirocumab (anti-PCSK9) inhibits *PCSK9. Alirocumab (anti-PCSK9) reduces NLRP3 inflammasome, regulates Nrf2/HO-1, HMGB1/NF-κB* and Fractalkine/CX3CR1. Alirocumab (anti-PCSK9) increases the ability of the liver to bind LDL-cholesterol (LDL-C) and reduces levels of LDL-C in blood. Alirocumab (anti-PCSK9) improves atherosclerosis and inflammation .

HY-161938

BRD8518	PCSK9 LDLR	Metabolic Disease
BRD8518 is a *PCSK9* inhibitor (EC₅₀=0.23 μM). BRD8518 lowers blood lipids by upregulating LDLR expression and stimulating LDL uptake. BRD8518 can be used in the study of cardiovascular diseases .

HY-163794

DC371739	ANGPTL PCSK9	Metabolic Disease
DC371739 is a potent and orally activity *PCSK9* inhibitor. DC371739 decreases the mRNA expression of PCSK9 and ANGPTL3. DC371739 decreases the protein expression of PCSK9 and increases the protein expression of LDLR. DC371739 has the potential for the research of hyperlipidemia .

HY-148689

SPC4061	PCSK9	Metabolic Disease
SPC4061 an antisense nucleotide, is a potent *PCSK9* inhibitor. SPC4061 targets the lock-in nucleic acid (LNA) of PCSK9 for the study of hypercholesterolemia and related diseases .

HY-148689A

SPC4061 sodium	PCSK9	Metabolic Disease
SPC4061 an antisense nucleotide, sodium is a potent *PCSK9* inhibitor. SPC4061 targets the lock-in nucleic acid (LNA) of PCSK9 for the study of hypercholesterolemia and related diseases .

HY-147252

Bezeparsen	PCSK9	Metabolic Disease
Bezeparsen is a PCSK9 synthesis inhibitor .

HY-147252A

Bezeparsen sodium	PCSK9	Metabolic Disease
Bezeparsen sodium is a PCSK9 synthesis inhibitor .

HY-101354

R-IMPP PF-00932239	PCSK9	Cardiovascular Disease Cancer
R-IMPP (PF-00932239) is an anti-secretagogue of *PCSK9* (IC₅₀=4.8 μM), which targets the 80S ribosome to inhibit PCSK9 protein translation .

HY-12402

SBC-115076 1 Publications Verification	PCSK9	Cardiovascular Disease
SBC-115076 is a potent proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor. PCSK9 is a proprotein convertase, which plays a crucial role in LDL receptor metabolism .

HY-120088A

PF-06446846 hydrochloride 3 Publications Verification	PCSK9	Cardiovascular Disease
PF-06446846 hydrochloride is an orally active and highly selective inhibitor of translation of Proprotein convertase subtilisin/kexin type 9 (PCSK9). PF-06446846 hydrochloride inhibits PCSK9 by inducing the ribosome to stall around codon 34 .

HY-120088

PF-06446846	PCSK9	Cardiovascular Disease
PF-06446846 is an orally active proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor. PF-06446846 directly and selectively inhibits translation of PCSK9 by stalling the 80S ribosome in the proximity of codon region .

HY-P99816

Ralpancizumab	PCSK9	Metabolic Disease
Ralpancizumab is a selective *PCSK9* inhibitor with potential application in hemorrhagic stroke .

HY-112598

PF-06815345	PCSK9	Metabolic Disease
PF-06815345 is an orally active and potent inhibitor of proprotein convertase subtilisin/kexin type 9 (PCSK9) with an IC₅₀ value of 13.4 μM. PF-06815345 significantly decreases the PCSK9 level in vivo in mouse .

HY-112598A

PF-06815345 hydrochloride	PCSK9	Cardiovascular Disease Metabolic Disease
PF-06815345 hydrochloride is an orally active and potent inhibitor of proprotein convertase subtilisin/kexin type 9 (PCSK9) with an IC₅₀ value of 13.4 μM. PF-06815345 hydrochloride significantly decreases the PCSK9 level in vivo in mouse .

HY-143219

SS-Inclisiran sodium	PCSK9	Cardiovascular Disease Others
SS-Inclisiran (sodium) is a sense strand of Inclisiran. Inclisiran is a double-stranded small interfering RNA (siRNA) molecule that inhibits the transcription of *PCSK-9* .

HY-158827A

AZD8233 sodium	PCSK9	Metabolic Disease
AZD8233 sodium, a liver-targeting antisense oligonucleotide (ASO), inhibits subtilisin/kexin type 9 (PCSK9) protein synthesis. AZD8233 sodium increases the available LDL receptors by reducing PCSK9 levels, thereby clearing LDL from the blood and decreasing LDL-C levels.

HY-161939

7030B-C5	PCSK9	Cardiovascular Disease
7030B-C5 is a *PCSK9* inhibitor (IC₅₀=1.61 μM). 7030B-C5 can significantly reduce plasma cholesterol and triglyceride (TG) levels in vivo and slow the progression of atherosclerosis. 7030B-C5 can be used in the study of cardiovascular diseases .

HY-143220

SS(no Galnac)-Inclisiran sodium	PCSK9	Cardiovascular Disease
SS(no Galnac)-Inclisiran (sodium) is a single stran Inclisiran with no GalNAc. Inclisiran is a double-stranded small interfering RNA (siRNA) molecule that inhibits the transcription of *PCSK-9* .

HY-158827

AZD8233	PCSK9	Metabolic Disease
AZD8233, a liver-targeting antisense oligonucleotide (ASO), inhibits proprotein convertase subtilisin/kexin type 9 (PCSK9) protein synthesis. AZD8233 increases the available LDL receptors by reducing PCSK9 levels, thereby clearing LDL from the blood and decreasing LDL-C levels.

HY-N2127

Pinostrobin 1 Publications Verification	Amyloid-β Apoptosis Ser/Thr Protease HSV Interleukin Related	Infection Cardiovascular Disease Neurological Disease Inflammation/Immunology Cancer
Pinostrobin is a flavonoid with anti-cancer, antioxidant, antiviral and neuroprotective activities. Pinostrobin has oral activity. Pinostrobin is a potent *PCSK9* inhibitor that inhibits the catalytic activity of *PCSK9*. Pinostrobin can be used in the research of viral infections, cancer, leukemia, cardiovascular and cerebrovascular diseases, cirrhosis, inflammation and neurological diseases .

HY-161941

MeIm	LDLR PCSK9	Cardiovascular Disease
MeIm (compound 7) is a high-affinity *PCSK9* targeting peptide mimetic with cholesterol-lowering activity. MeIm increases cellular uptake of LDL (EC₅₀=6.04 μM) by inhibiting the binding of *PCSK9* to LDLR (IC₅₀=11.2 μM). MeIm can be used in the study of cardiovascular diseases .

HY-141714

SBC-115337	PCSK9	Cardiovascular Disease Cancer
SBC-115337, as a potent benzofuran compound, is a *PCSK9* inhibitor with an IC₅₀ value of 0.5 μM .

HY-P2276

Pep2-8	PCSK9	Cancer
Pep2-8 is a *PCSK9* inhibitor with a binding K_D of 0.7 μM and an IC₅₀ of 1.4 μM .

HY-143221

AS-Inclisiran sodium	PCSK9	Cardiovascular Disease
AS-Inclisiran sodium is the antisense of Inclisiran. Inclisiran (ALN-PCSsc) is a double-stranded small interfering RNA (siRNA) molecule that inhibits the transcription of *PCSK-9*. Inclisiran can be used for hyperlipidemia and cardiovascular disease (CVD) research .

HY-101832

SBC-110736 1 Publications Verification	PCSK9	Cardiovascular Disease Metabolic Disease
SBC-110736 is a proprotein convertase subtilisin kexin type 9 (PCSK9) inhibitor extracted from patent WO2014150395A1 .

Cat. No.	Product Name	Target	Research Area

HY-P2276

Pep2-8	PCSK9	Cancer
Pep2-8 is a *PCSK9* inhibitor with a binding K_D of 0.7 μM and an IC₅₀ of 1.4 μM .

HY-P4153

Enlicitide chloride MK-0616 chloride	PCSK9	Cardiovascular Disease
Enlicitide chloride is an orally active inhibitor for *PCSK9* that blocks the interaction between LPL receptor and PSCK9, with an IC₅₀ of 2.5 nM. Enlicitide chloride can be used in the study of cardiovascular diseases such as atherosclerosis, hypercholesterolemia, coronary heart disease, metabolic syndrome, acute coronary syndrome or related cardiovascular and cardiometabolic disorders .

Cat. No.	Product Name	Target	Research Area

HY-P9928A

Alirocumab (anti-PCSK9) 1 Publications Verification REGN 727(anti-PCSK9); SAR 236553(anti-PCSK9)	PCSK9 NOD-like Receptor (NLR) Keap1-Nrf2 HMG Family NF-κB CX3CR1	Cardiovascular Disease Cancer
Alirocumab (anti-PCSK9) is an anti-PCSK9 human monoclonal antibody. Alirocumab (anti-PCSK9) inhibits *PCSK9. Alirocumab (anti-PCSK9) reduces NLRP3 inflammasome, regulates Nrf2/HO-1, HMGB1/NF-κB* and Fractalkine/CX3CR1. Alirocumab (anti-PCSK9) increases the ability of the liver to bind LDL-cholesterol (LDL-C) and reduces levels of LDL-C in blood. Alirocumab (anti-PCSK9) improves atherosclerosis and inflammation .

HY-P99552

Tafolecimab IBI-306	PCSK9	Cardiovascular Disease
Tafolecimab (IBI-306) is a human lgG2 monoclonal antibody that specifically binds *PCSK-9* and reduces LDL-C levels by inhibiting PCSK-9-mediated endocytosis of the LDL receptor, which in turn enhances clearance of LDL-C and leads to a reduction in LDL-C levels. Tafolecimab may be used in studies of hypercholesterolaemia .

HY-P9930

Evolocumab 2 Publications Verification AMG 145	NF-κB Ser/Thr Protease Toll-like Receptor (TLR)	Cardiovascular Disease Metabolic Disease Inflammation/Immunology Cancer
Evolocumab (AMG 145) is a human monoclonal antibody that inhibits *PCSK9. Evolocumab is used in the study of hypercholesterolemia and atherosclerotic cardiovascular disease. Evolocumab binds to circulating PCSK9* protein and inhibits its binding to LDLR. Evolocumab has antioxidant and cytoprotective activities against H₂O₂-induced oxidative damage to endothelial cells. Evolocumab may also negatively regulate activation of the TLR-4/NF-κB signaling pathway to prevent inflammation .

HY-P9928

Alirocumab 1 Publications Verification REGN 727; SAR 236553	PCSK9 NOD-like Receptor (NLR) Keap1-Nrf2 HMG Family NF-κB CX3CR1	Cardiovascular Disease Cancer
Alirocumab is an anti-PCSK9 human monoclonal antibody. Alirocumab inhibits *PCSK9. Alirocumab reduces NLRP3 inflammasome, regulates Nrf2/HO-1, HMGB1/NF-κB* and Fractalkine/CX3CR1. Alirocumab increases the ability of the liver to bind LDL-cholesterol (LDL-C) and reduces levels of LDL-C in blood. Alirocumab improves atherosclerosis and inflammation .

HY-P99626

Frovocimab LY 3015014	PCSK9	Metabolic Disease
Frovocimab (LY 3015014) is a humanized IgG4 monoclonal antibody (mAb) that neutralizes *PCSK9. Frovocimab inhibits* PCSK9 binding to LDL receptor (LDLR) while permitting the normal proteolytic cleavage of the bound intact PCSK9 .

HY-P99816

Ralpancizumab	PCSK9	Metabolic Disease
Ralpancizumab is a selective *PCSK9* inhibitor with potential application in hemorrhagic stroke .

Cat. No.	Product Name		Classification

HY-143219

SS-Inclisiran sodium		siRNAs siRNA drugs
SS-Inclisiran (sodium) is a sense strand of Inclisiran. Inclisiran is a double-stranded small interfering RNA (siRNA) molecule that inhibits the transcription of *PCSK-9* .

HY-143220

SS(no Galnac)-Inclisiran sodium		siRNAs siRNA drugs
SS(no Galnac)-Inclisiran (sodium) is a single stran Inclisiran with no GalNAc. Inclisiran is a double-stranded small interfering RNA (siRNA) molecule that inhibits the transcription of *PCSK-9* .

HY-143221

AS-Inclisiran sodium		siRNAs siRNA drugs
AS-Inclisiran sodium is the antisense of Inclisiran. Inclisiran (ALN-PCSsc) is a double-stranded small interfering RNA (siRNA) molecule that inhibits the transcription of *PCSK-9*. Inclisiran can be used for hyperlipidemia and cardiovascular disease (CVD) research .

HY-150223

GalNAc unconjugated/naked Inclisiran 1 Publications Verification		siRNAs siRNA drugs
GalNAc unconjugated/naked Inclisiran is a double-stranded small interfering RNA (siRNA) without GalNAc conjugation. GalNAc unconjugated/naked Inclisiran inhibits the transcription of *PCSK-9*, and can be used for hyperlipidemia and cardiovascular disease (CVD) research .

HY-148689

SPC4061		Antisense Oligonucleotides
SPC4061 an antisense nucleotide, is a potent *PCSK9* inhibitor. SPC4061 targets the lock-in nucleic acid (LNA) of PCSK9 for the study of hypercholesterolemia and related diseases .

HY-148689A

SPC4061 sodium		Antisense Oligonucleotides
SPC4061 an antisense nucleotide, sodium is a potent *PCSK9* inhibitor. SPC4061 targets the lock-in nucleic acid (LNA) of PCSK9 for the study of hypercholesterolemia and related diseases .

HY-147252

Bezeparsen		Antisense Oligonucleotides
Bezeparsen is a PCSK9 synthesis inhibitor .

HY-147252A

Bezeparsen sodium		Antisense Oligonucleotides
Bezeparsen sodium is a PCSK9 synthesis inhibitor .

HY-158827A

AZD8233 sodium		Antisense Oligonucleotides
AZD8233 sodium, a liver-targeting antisense oligonucleotide (ASO), inhibits subtilisin/kexin type 9 (PCSK9) protein synthesis. AZD8233 sodium increases the available LDL receptors by reducing PCSK9 levels, thereby clearing LDL from the blood and decreasing LDL-C levels.

HY-158827

AZD8233		Antisense Oligonucleotides
AZD8233, a liver-targeting antisense oligonucleotide (ASO), inhibits proprotein convertase subtilisin/kexin type 9 (PCSK9) protein synthesis. AZD8233 increases the available LDL receptors by reducing PCSK9 levels, thereby clearing LDL from the blood and decreasing LDL-C levels.

HY-158825

Cepadacursen sodium CIVI007 sodium		Antisense Oligonucleotides
Cepadacursen sodium is a liver-targeting antisense oligonucleotide (ASO), inhibits proprotein convertase subtilisin/kexin type 9 (PCSK9) protein synthesis. Cepadacursen sodium can be used for hypercholesterolemia treatment and the prevention of atherosclerotic cardiovascular disease (ASCVD).

HY-132591

Inclisiran 2 Publications Verification ALN-PCSsc		siRNAs siRNA drugs
Inclisiran is a double-stranded small interfering RNA (siRNA) molecule. Inclisiran inhibits the transcription of *PCSK9. Inclisiran inhibits* Pyroptosis, activates PPARγ, and reduces NLRP3, cleaved caspase-1, IL-1β, and IL-18. Inclisiran has anti-inflammatory, lipid-regulating and anti-atherosclerotic activities. Inclisiran can be used in researches of hyperlipidemia and cardiovascular disease (CVD) .

HY-132591A

Inclisiran sodium 2 Publications Verification ALN-PCSsc sodium		siRNAs siRNA drugs
Inclisiran sodium is a double-stranded small interfering RNA (siRNA) molecule. Inclisiran sodium inhibits the transcription of *PCSK9. Inclisiran sodium inhibits* Pyroptosis, activates PPARγ, and reduces NLRP3, cleaved caspase-1, IL-1β, and IL-18. Inclisiran sodium has anti-inflammatory, lipid-regulating and anti-atherosclerotic activities. Inclisiran sodium can be used in researches of hyperlipidemia and cardiovascular disease (CVD) .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

PCSK9 inhibitor

Inhibitors & Agonists

Peptides

Inhibitory Antibodies

NaturalProducts

Oligonucleotides

Natural
Products